Although Novartis and Kite brought them to market, aren't - from what I've read in several papers (correct me if I'm mistaken) - the vast majority of clinical trials in this area still publicly funded? (NIH/NCI grants)
Public funds are used up to proof of concept and sometimes early tox/CMC (often through a CRO), but the bulk of the funding for trials comes from industry.